Histology

E. Sabattini

Use of circulating tumor DNA to genotype aggressive lymphomas

D. Rossi

Practical considerations for using genome sequencing data for patient selection

D.W. Scott

Molecular predictors of response

M.A. Shipp

Precision medicine in the era of combination therapy: introduction to the MasterLymph protocol

A. Younes

The laboratory challenge

D.W. Scott

The clinical challenge of double hit lymphoma

W.H. Wilson

The clinical challenge of double espressor lymphoma

B.D. Cheson

How to treat early stage DLBCL

W.H. Wilson

Advanced stage: moving beyond R-CHOP? - the addition of ibrutinib

A. Younes

Advanced stage: moving beyond R-CHOP? - the addition of lenalidomide

T.E. Witzig

How to treat elderly patients

L. Balducci

Why doesn’t everyone respond? Primary and secondary resistance to signaling pathway

W.H. Wilson

Role of radiotherapy

U. Ricardi

Transplant

I. Khouri

Innovative imaging tools

M. Meignan

Transcend Study

J.S. Abramson

ZUMA-1 Study

S.S. Neelapu

CC-122

J.M. Michot

Polatuzumab vedotin

R. Advani

Checkpoint inhibitors

S.M. Ansell

Pixantrone

R. Pettengell

Brentuximab vedotin

J.S. Abramson

Umbralisib

O.A. O’Connor

Copanlisib

W.S. Kim

MOR208

W. Jurczak

Selinexor

J. Kuruvilla

Biosimilar Rituximab

W. Jurczak

Bispecific monoclonal antibodies

M. Hutchings

Cutaneos T-cell lymphoma

J. Scarisbrick

Burkitt lymphoma

J.S. Abramson

Mantle cell lymphoma

S. Rule

Peripheral T-cell lymphoma

R. Advani

NK/T-cell lymphoma

W.S. Kim

Primary CNS

C. Soussain